Dupont Charlotte, Grateau Sophie, Moreau Emilie, Johnson Nicolaï, Rivet-Danon Diane, Cristofari Sarra, Prades Marie, Lévy Rachel, Kolanska Kamila, Chabbert-Buffet Nathalie, Sermondade Nathalie
Service de Biologie de la Reproduction CECOS, Hôpital Tenon (AP-HP), Sorbonne-Université 75020 PARIS, France; Sorbonne Université, Centre de recherche Saint-Antoine, Inserm US938 75012 PARIS, France.
Service de Biologie de la Reproduction CECOS, Hôpital Tenon (AP-HP), Sorbonne-Université 75020 PARIS, France.
J Gynecol Obstet Hum Reprod. 2025 Feb;54(2):102893. doi: 10.1016/j.jogoh.2024.102893. Epub 2024 Dec 7.
Transgender men face reproductive challenges due to the potential impact on fertility of gender-affirming hormone therapy (GAHT) and surgical interventions. Testosterone therapy during "female to male" transition leads to anovulation and amenorrhea. Although these effects are typically reversible upon stopping treatment, the long-term effects of androgens on future fertility and health of potential children remain poorly known. Despite being long overlooked, the desire for parenthood is a significant reality among transgender men. Advances in medical techniques and legislative changes now make fertility preservation (FP), primarily through oocyte cryopreservation, possible for transgender men. Yet, published data on FP outcomes for this population are still limited.
We conducted a retrospective study to compare ovarian stimulation outcomes between transgender men and presumed fertile women from an oocyte donation program.
Between June 2018 and February 2022, 118 transgender men were referred to the FP consultation, of whom 13 ultimately underwent FP through oocyte vitrification following ovarian stimulation. These 13 individuals were compared to a control group of 13 matched female oocyte donors. We did not observe any significant difference in the clinical and biological outcomes of ovarian stimulation, including duration of stimulation, total FSH dose administered, number of oocytes retrieved, and number of mature oocytes obtained.
Our experience suggests that FP through oocyte vitrification after ovarian stimulation is feasible and effective for transgender men, with outcomes comparable to those of cisgender women of the same age. Larger studies are necessary to validate these findings and assess the long-term success rates.
由于性别确认激素疗法（GAHT）和手术干预对生育能力的潜在影响，跨性别男性面临生殖挑战。“女性向男性”转变过程中的睾酮疗法会导致无排卵和闭经。尽管这些影响在停止治疗后通常是可逆的，但雄激素对未来生育能力和潜在子女健康的长期影响仍知之甚少。尽管长期以来一直被忽视，但生育愿望在跨性别男性中是一个重要的现实。现在，医疗技术的进步和立法的变化使跨性别男性主要通过卵母细胞冷冻保存生育成为可能。然而，关于该人群生育力保存（FP）结果的已发表数据仍然有限。
我们进行了一项回顾性研究，以比较来自卵母细胞捐赠项目的跨性别男性和假定有生育能力的女性之间的卵巢刺激结果。
在2018年6月至2022年2月期间，118名跨性别男性被转介进行生育力保存咨询，其中13人最终在卵巢刺激后通过卵母细胞玻璃化进行了生育力保存。将这13人与13名匹配的女性卵母细胞捐赠者组成的对照组进行比较。我们没有观察到卵巢刺激的临床和生物学结果有任何显著差异，包括刺激持续时间、给予的总促卵泡素剂量、回收的卵母细胞数量和获得的成熟卵母细胞数量。
我们的经验表明，卵巢刺激后通过卵母细胞玻璃化进行生育力保存对跨性别男性是可行且有效的，其结果与同年龄的顺性别女性相当。需要更大规模的研究来验证这些发现并评估长期成功率。
